Companies › EBS

EMERGENT BIOSOLUTIONS INC (EBS)

Institutional ownership, SEC filings and insider activity

Sector: Healthcare & Pharma · SEC CIK 0001367644 · EDGAR filings · Updated 2026-07-28

EMERGENT BIOSOLUTIONS INC (EBS) has reported institutional ownership of 83.4%, with 188 institutional managers holding positions valued at $357.2M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.

Filings this week (1)

• 2026-07-28 — SCHEDULE 13G/A filed

Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.

Latest updates

• 2026-07-02 — Insider transaction reported (Form 4)
• 2026-07-01 — Notice of proposed sale filed (Form 144)
• 2026-06-29 — Current report (8-K) filed
• 2026-06-10 — Insider transaction reported (Form 4)
• 2026-06-10 — Insider transaction reported (Form 4)

Institutional ownership overview

According to SEC 13F filings tracked by Sightfile, EMERGENT BIOSOLUTIONS INC has 188 institutional holders and institutional ownership of 83.4%.

Insider activity

Insiders reported 51 transactions (1 buys, 8 sells) across 17 reporting insiders, with a net reported value of −$672.6K.

Data flags from SEC filings

Related companies

CYTEK BIOSCIENCES INC (CTKB) · NATURES SUNSHINE PRODS INC (NATR) · SHATTUCK LABS INC (STTK) · ANTERIS TECHNOLOGIES GLOBAL (AVR) · REGENXBIO INC (RGNX) · SUTRO BIOPHARMA INC (STRO)